Effects of bradykinin in the cardiovascular effects of angiotensin-converting enzyme inhibitors
Galinier, M.; Pathak, A.; Baixas, C.; Alhabaj, S.; Fallouh, V.; Roncali, J.; Schmutz, L.; Massabuau, P.; Fauvel, J.M.; Bounhoure, J.P.
Archives des Maladies du Coeur et des Vaisseaux 95 Spec 4(5 Spec 4: 37-40
2002
ISSN/ISBN: 0003-9683 PMID: 11933554 Document Number: 6648
The role of bradykinin in the cardiovascular effects of angiotensin converting enzyme inhibitors remains difficult to establish. On their haemodynamic effects, bradykinin acts during their acute administration, participating in their vasodilatation action, while during their chronic administration they act slightly or not at all. On their trophic effects, the action of the tissue kallikrein-kinin system, suggested by the results of animal experimentation, is yet to be demonstrated in man. For their effects on cardiovascular morbidity and mortality the role of bradykinin remains under discussion. Nevertheless, besides ACE inhibitors, the other therapeutic agents which increase the levels of bradykinin, such as neutral endopeptidase inhibitors, have a significant field of development in the course of cardiovascular pathologies.
Document emailed within 1 workday
